Quantity of eligible individuals: CDEC talked about the uncertainty in the amount of sufferers with moderately extreme to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some individuals who are classified as having moderate or average disorder could possibly have